Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SS Innovations International ( (SSII) ) just unveiled an update.
On January 13, 2026, SS Innovations International announced preliminary unaudited results indicating a sharp acceleration in sales of its SSi Mantra surgical robotic system for the fourth quarter and full year ended December 31, 2025. The company expects fourth-quarter 2025 revenue of about $15.0 million, an 85% increase from the prior-year period, driven by a 68% rise in SSi Mantra installations to 37 units, while full-year 2025 revenue is projected at roughly $43.0 million, up 108% year on year, with installations more than doubling to 103 units and lifting the global installed base to 168 systems. Management attributed the performance to strong demand in India and international markets and highlighted ongoing efforts to extend its footprint into the U.S. and Europe, where regulatory reviews are under way, underscoring the company’s bid to solidify its position in the growing surgical robotics market even as the figures remain preliminary and subject to final audit.
The most recent analyst rating on (SSII) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
Spark’s Take on SSII Stock
According to Spark, TipRanks’ AI Analyst, SSII is a Neutral.
The score is held down primarily by weak financial quality (continued losses and negative operating cash flow) and bearish technicals (trading below major moving averages with negative MACD). Positive corporate events (FDA submission and product milestones) provide upside potential, but valuation remains constrained by unprofitability and the lack of a dividend.
To see Spark’s full report on SSII stock, click here.
More about SS Innovations International
SS Innovations International, Inc. is a medical technology company focused on developing innovative surgical robotic systems to make robotic surgery more affordable and accessible globally. Its product portfolio includes the proprietary SSi Mantra surgical robotic system and the SSi Mudra suite of surgical instruments, which support a wide range of robotic procedures, including cardiac surgery. Although an American company, it is headquartered in India and is pursuing broader international expansion for its cost-effective, user-friendly robotic solutions.
Average Trading Volume: 97,193
Technical Sentiment Signal: Sell
Current Market Cap: $1.07B
For an in-depth examination of SSII stock, go to TipRanks’ Overview page.